In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia
Ho Jae Han(Seoul National University), Dennis Dong Hwan Kim(University Health Network), Eunju Park(Daegu Gyeongbuk Institute of Science and Technology), Amirthagowri Ambalavanan(Queen's University), Michael W. Deininger(Versiti Blood Center of Wisconsin), Anthea Travas(University Health Network), Jaeyoon Kim(LG (United States)), Jong‐Won Kim(Samsung Medical Center), Danielle Pyne(University Health Network), Shinya Kimura(Saga University)
Cited by 0
Related Papers
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter.
|Molecular Pharmacology|1992|481
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464